免疫炎症因子在肝内胆管癌中的预测价值

刘桂玲; 窦杰; 孟慧娟; 马炳奇

doi:10.3969/j.issn.1001-5256.2023.09.030

免疫炎症因子在肝内胆管癌中的预测价值

DOI: 10.3969/j.issn.1001-5256.2023.09.030

刘桂玲¹,
窦杰¹,
孟慧娟²,
马炳奇^1, , ,

1.
潍坊医学院附属医院，肝胆胰外科，山东潍坊 261031
2.
潍坊医学院附属医院，皮肤科，山东潍坊 261031

基金项目:

潍坊市科学技术发展计划（医学类） (2022YX026);

潍坊医学院附属医院科研创新计划项目 (2022BSQD07);

山东省医药卫生科技发展计划项目 (202004011537)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：刘桂玲负责查阅文献，撰写文章；窦杰参与论文起草；孟慧娟参与论文起草，修改文章关键内容；马炳奇负责提出论文思路，参与论文指导，修改文章并最后定稿。

详细信息

通信作者:
马炳奇， mabingqi@126.com （ORCID： 0000－0001－9314－6559）

计量
- 文章访问数: 281
- HTML全文浏览量: 65
- PDF下载量: 27
- 被引次数: 0
出版历程
- 收稿日期: 2023-03-28
- 录用日期: 2023-04-30
- 出版日期: 2023-09-19

Value of immune－inflammatory factors in predicting intrahepatic cholangiocarcinoma

1.
Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University，Weifang，Shandong 261031，China
2.
Department of Dermatology，Affiliated Hospital of Weifang Medical University，Weifang，Shandong 261031，China

Research funding:

Weifang Science and Technology Development Program （Medical Science） (2022YX026);

Scientific Research and Innovation Project of Affiliated Hospital of Weifang Medical University (2022BSQD07);

Medical and Health Science and Technology Development Plan of Shandong Province (202004011537)

More Information

Corresponding author: MA Bingqi， mabingqi@126.com （ORCID： 0000－0001－9314－6559）

摘要

摘要: 肝内胆管癌（ICC）是最常见的原发性肝脏恶性肿瘤之一，在过去20年中发病率持续上升。手术切除是ICC的主要治疗方式，但超半数患者在初诊时已失去手术机会，只能选择局部区域治疗或系统治疗。目前ICC的治疗效果并不理想。在ICC和其他实体肿瘤中，已发现一些炎症指标可能有效反映肿瘤内部的炎症状态，这些免疫炎症因子（IIF）与肿瘤进展及预后指标存在着明显的相关性，其均是基于血常规、C反应蛋白、白蛋白和肿瘤标志物等血液学指标计算得出，并可以分为三大类：直接炎症因子、肿瘤标志物和联合炎症因子。经过对比分析发现，联合炎症因子在ICC患者预后中的预测价值优于直接炎症因子和肿瘤标志物。推荐使用IIF中的炎症和肿瘤指标预后评分、全身炎症评分或全身炎症反应指数作为ICC患者生存预后的评分系统。
- 胆管上皮癌 /
- 生物标记，肿瘤 /
- 预后
Abstract: Intrahepatic cholangiocarcinoma （ICC） is one of the most common primary liver malignancies， with an increasing incidence rate in the past two decades. Surgical resection is the main treatment method for ICC， but more than half of the patients have lost the opportunity for surgery at the time of initial diagnosis， with the only choice of locoregional or systemic treatment. At present， there is still a lack of satisfactory treatment outcomes for ICC. In ICC and other solid tumors， it has been found that some immune－inflammatory factors （IIFs） can effectively reflect the inflammatory state within the tumor， and these IIFs are significantly associated with tumor progression and prognostic markers. These IIFs are all calculated based on hematological parameters such as routine blood test results， C－reactive protein， albumin， and tumor markers， and they can be classified into three categories， i.e.， direct inflammatory factors， tumor markers， and combined inflammatory factors. Comparative analysis has shown that combined inflammatory factors has a better value than direct inflammatory factors and tumor markers in predicting the prognosis of ICC patients. It is recommended to use prognostic inflammatory and tumor score， systemic inflammation score， and systemic inflammation response index as the scoring systems for evaluating the survival and prognosis of ICC patients.
- Cholangiocarcinoma /
- Biomarkers， Tumor /
- Prognosis

HTML全文

表 1 ICC中IIF的分类、计算标准及截断值

Table 1. The classification， calculation criteria and cutoff value of IIF in ICC

IIF	计算标准	截断值
直接炎症因子
NLR^{［17，19，24］}	中性粒细胞计数（10⁹/L）/淋巴细胞计数（10⁹/L）	2.94^［17］；3.00^［19］；5.0^［24］
PLR^{［17，19，25］}	血小板计数（10⁹/L）/淋巴细胞计数（10⁹/L）	130.59^［17］；90.0^［19］；150^［25］
LMR^{［17，19，23］}	淋巴细胞计数（10⁹/L）/单核细胞计数（10⁹/L）	3.62^［17］；2.70^［19］；4.45^［23］
PII^［19］	中性粒细胞计数（10⁹/L）×单核细胞计数（10⁹/L）/淋巴细胞计数（10⁹/L）	1.50
SII^［20］	中性粒细胞计数（10⁹/L）×血小板计数（10⁹/L）/淋巴细胞计数（10⁹/L）	867.4
IS^［21］	0分：NLR<1.93且LMR≥4.78 1分：NLR≥1.93且LMR≥4.78/NLR<1.93且LMR<4.78 2分：NLR≥1.93且LMR<4.78
肿瘤标志物
CA19－9^{［18－19，23］}		39.0^［18］；76.0^［19］；89.0^［23］
CEA^{［18－19，25］}		5.00^［18］；4.50^［19］；7.0^［25］
CA242^［19］		30.0
Fer^［19］		150
联合炎症因子
PNI^{［16－17］}	Alb（g/L）+5×淋巴细胞计数（10⁹/L）	48.25^［16］；36.7^［17］
GPS^［17］	0分：CRP≤10 mg/L且Alb≥35 g/L 1分：CRP≤10 mg/L且Alb<35 g/L/CRP>10 mg/L且Alb≥35 g/L 2分：CRP>10 mg/L且Alb<35 g/L
mGPS^［17］	0分：CRP≤10 mg/L 1分：CRP>10 mg/L且Alb≥35 g/L 2分：CRP>10 mg/L且Alb<35 g/L
PI^［17］	0分：CRP≤10 mg/L且WBC≤11×10⁹/L 1分：CRP≤10 mg/L且WBC>11×10⁹/L/CRP>10 mg/L且WBC≤11×10⁹/L 2分：CRP>10 mg/L且WBC>11×10⁹/L
PITS^［22］	1级：PII<1.5且CA19－9<76.0 U/mL 2级：PII≥1.5，CA19－9<76.0 U/mL/PII<1.5且CA19－9≥76.0 U/mL 3级：PII≥1.5且CA19－9≥76.0 U/mL
SIS^［23］	1级：CA19－9<89 U/mL且LMR≥4.45 2级：CA19－9≥89 U/mL且LMR≥4.45/CA19－9<89 U/mL且LMR<4.45 3级：CA19－9≥89 U/mL且LMR<4.45
SIR^［24］	①CA19－9≥500 IU/mL；②NLR≥5；③CRP≥5 mg/L 1级：均不满足上述条件 2级：只有1项满足上述条件 3级：2～3项满足上述条件
PPS^［25］	0分：CEA≤7.0 ng/mL；Alb≥35 g/L；CRP≤0.5 mg/dL；PLR≤150 1分：CEA>7.0 ng/mL；Alb<35 g/L；CRP>0.5 mg/dL；PLR>150 PPS为上述4项指标的总和
注：PII，预后炎症指数；IS，炎症评分；CA19－9，糖类抗原19－9；CEA，癌胚抗原；CA242，糖类抗原242；Fer，铁蛋白；PNI，营养预后指标；mGPS，修正的GPS评分；SIR，全身炎症反应指数；PPS，术前预后评分。

下载: 导出CSV

参考文献(26)

[1]	KELLEY RK, BRIDGEWATER J, GORES GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 72( 2): 353－ 363. DOI: 10.1016/j.jhep.2019.10.009.
[2]	MA B, MENG H, TIAN Y, et al. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma[J]. BMC Cancer, 2020, 20( 1): 318. DOI: 10.1186/s12885－020－06804－6.
[3]	ZHANG H, YANG T, WU M, et al. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management[J]. Cancer Lett, 2016, 379( 2): 198－ 205. DOI: 10.1016/j.canlet.2015.09.008.
[4]	BRIDGEWATER J, GALLE PR, KHAN SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60( 6): 1268－ 1289. DOI: 10.1016/j.jhep.2014.01.021.
[5]	Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group. Chinese expert consensus on management of intrahepatic cholangiocarcinoma(2022 edition)[J]. Chin J Dig Surg, 2022, 21( 10): 1269－ 1301. DOI: 10.3760/cma.j.cn115610－20220829－00476. 中国抗癌协会肝癌专业委员会胆管癌协作组. 原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21( 10): 1269－ 1301. DOI: 10.3760/cma.j.cn115610－20220829－00476.
[6]	PRIMROSE JN, FOX RP, PALMER DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20( 5): 663－ 673. DOI: 10.1016/S1470－2045(18)30915－X.
[7]	VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362( 14): 1273－ 1281. DOI: 10.1056/NEJMoa0908721.
[8]	OKUSAKA T, NAKACHI K, FUKUTOMI A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan[J]. Br J Cancer, 2010, 103( 4): 469－ 474. DOI: 10.1038/sj.bjc.6605779.
[9]	OH DY, CHEN LT, HE AR, et al. A phase III, randomized, double－blind, placebo－controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ－1[J]. Ann Oncol, 2019, 30( Suppl 5): v319. DOI: 10.1093/annonc/mdz247.157.
[10]	MURATA M. Inflammation and cancer[J]. Environ Health Prev Med, 2018, 23( 1): 50. DOI: 10.1186/s12199－018－0740－1.
[11]	LEI X, LEI Y, LI JK, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy[J]. Cancer Lett, 2020, 470: 126－ 133. DOI: 10.1016/j.canlet.2019.11.009.
[12]	JOB S, RAPOUD D, DOS SANTOS A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72( 3): 965－ 981. DOI: 10.1002/hep.31092.
[13]	MA B, MENG H, TIAN Y, et al. High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma[J]. Oncol Lett, 2021, 21( 1): 69. DOI: 10.3892/ol.2020.12330.
[14]	WANG DS, LUO HY, QIU MZ, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer[J]. Med Oncol, 2012, 29( 5): 3092－ 3100. DOI: 10.1007/s12032－012－0226－8.
[15]	KINOSHITA A, ONODA H, IMAI N, et al. Comparison of the prognostic value of inflammation－based prognostic scores in patients with hepatocellular carcinoma[J]. Br J Cancer, 2012, 107( 6): 988－ 993. DOI: 10.1038/bjc.2012.354.
[16]	SALATI M, FILIPPI R, VIVALDI C, et al. The prognostic nutritional index predicts survival and response to first－line chemotherapy in advanced biliary cancer[J]. Liver Int, 2020, 40( 3): 704－ 711. DOI: 10.1111/liv.14314.
[17]	LIN J, FANG T, ZHU M, et al. Comparative performance of inflammation－based prognostic scores in patients operated for intrahepatic cholangiocarcinoma[J]. Cancer Manag Res, 2019, 11: 9107－ 9119. DOI: 10.2147/CMAR.S198959.
[18]	MA BQ, MENG HJ, ZHANG W, et al. Prognostic value of several immune and inflammatory indices after curative－intent resection for intrahepatic cholangiocarcinoma[J]. J Clin Hepatol, 2022, 38( 9): 2061－ 2066. DOI: 10.3969/j.issn.1001－5256.2022.09.021. 马炳奇, 孟慧娟, 张伟, 等. 多种免疫炎症指标对肝内胆管癌患者根治性切除术后预后的预测价值[J]. 临床肝胆病杂志, 2022, 38( 9): 2061－ 2066. DOI: 10.3969/j.issn.1001－5256.2022.09.021.
[19]	MA B, MENG H, SHEN A, et al. Prognostic value of inflammatory and tumour markers in small－duct subtype intrahepatic cholangiocarcinoma after curative－intent resection[J]. Gastroenterol Res Pract, 2021, 2021: 6616062. DOI: 10.1155/2021/6616062.
[20]	SELLERS CM, UHLIG J, LUDWIG JM, et al. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease[J]. Cancer Med, 2019, 8( 13): 5916－ 5929. DOI: 10.1002/cam4.2373.
[21]	OHIRA M, YOSHIZUMI T, YUGAWA K, et al. Association of inflammatory biomarkers with long－term outcomes after curative surgery for mass－forming intrahepatic cholangiocarcinoma[J]. Surg Today, 2020, 50( 4): 379－ 388. DOI: 10.1007/s00595－019－01905－7.
[22]	MA BQ, MENG HJ, DONG XF, et al. Predictive value of prognostic inflammatory and tumor score in intrahepatic cholangiocarcinoma[J]. Chin J Hepatol, 2022, 30( 7): 777－ 783. DOI: 10.3760/cma.j.cn501113－20211108－00539. 马炳奇, 孟慧娟, 董小锋, 等. 炎症和肿瘤指标预后评分在肝内胆管癌中的预测价值[J]. 中华肝脏病杂志, 2022, 30( 7): 777－ 783. DOI: 10.3760/cma.j.cn501113－20211108－00539.
[23]	ZHANG Y, SHI SM, YANG H, et al. Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection[J]. J Cancer, 2019, 10( 2): 494－ 503. DOI: 10.7150/jca.26890.
[24]	YOH T, SEO S, HATANO E, et al. A novel biomarker－based preoperative prognostic grading system for predicting survival after surgery for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2017, 24( 5): 1351－ 1357. DOI: 10.1245/s10434－016－5708－z.
[25]	SAITO H, NOJI T, OKAMURA K, et al. A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma[J]. Surgery, 2016, 159( 3): 842－ 851. DOI: 10.1016/j.surg.2015.10.027.
[26]	SU M, ZHAO DQ. Research advances of prognostic factors in intrahepatic cholangiocarcinoma[J/CD]. Chin J Gastrointestial Endoscopy(Electronic Editon), 2023, 10( 1): 62－ 66. DOI: 10.3877/cma.j.issn.2095－7157.2023.01.016. 苏淼, 赵东强. 肝内胆管癌预后因素的研究进展[J/CD]. 中华胃肠内镜电子杂志, 2023, 10( 1): 62－ 66. DOI: 10.3877/cma.j.issn.2095－7157.2023.01.016.